https://scholars.lib.ntu.edu.tw/handle/123456789/551623
標題: | Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Asia-Pacific region: results from the Dyslipidemia International Study II | 作者: | Poh K.-K. Ambegaonkar B. Baxter C.A. Brudi P. Buddhari W. FU-TIEN CHIANG Horack M. Jang Y. Johnson B. Lautsch D. Sawhney J.P.S. Vyas A. Yan B.P. Gitt A.K. |
關鍵字: | acute coronary syndrome; Cholesterol; coronary heart disease; lipids; myocardial infarction; statins | 公開日期: | 2018 | 卷: | 25 | 期: | 18 | 起(迄)頁: | 1950-1963 | 來源出版物: | European Journal of Preventive Cardiology | 摘要: | Background: As mortality due to cardiovascular disease increases throughout the world, accurate data on risk factors such as hyperlipidemia are required. This is lacking in the Asia-Pacific region. Design: The observational Dyslipidemia International Study (DYSIS) II was established to quantify the extent of hyperlipidemia in adults with acute and stable coronary heart disease globally. Methods: Patients with stable coronary heart disease or hospitalised with an acute coronary syndrome were enrolled across nine Asia-Pacific countries from July 2013 to October 2014. Lipid-lowering therapy and low-density lipoprotein cholesterol target attainment (<70 mg/dL) were assessed. The acute coronary syndrome cohort was followed up 4 months post-discharge. Results: Of the 4592 patients enrolled, 2794 had stable coronary heart disease and 1798 were admitted with an acute coronary syndrome. In the coronary heart disease cohort, the mean low-density lipoprotein cholesterol level was 86.9 mg/dL, with 91.7% using lipid-lowering therapy and 31% achieving low-density lipoprotein cholesterol of less than 70 mg/dL. In the acute coronary syndrome cohort at admission, the corresponding values were 103.2 mg/dL, 63.4% and 23.0%, respectively. Target attainment was significantly higher in lipid-lowering therapy-treated than non-treated patients in each cohort (32.6% vs. 12.9% and 31.1% vs. 9.0%, respectively). Mean atorvastatin-equivalent dosages were low (20 ± 15 and 22 ± 18 mg/day, respectively), with little use of non-statin adjuvants (13.0% and 6.8%, respectively). Low-density lipoprotein cholesterol target attainment had improved by follow-up for the acute coronary syndrome patients, but remained low (41.7%). Conclusions: Many patients in Asia at very high risk of recurrent cardiovascular events had a low-density lipoprotein cholesterol level above the recommended target. Although lipid-lowering therapy was common, it was not used to its full potential. ? The European Society of Cardiology 2018. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/551623 | ISSN: | 2047-4873 | DOI: | 10.1177/2047487318798927 | SDG/關鍵字: | atorvastatin; fluindostatin; low density lipoprotein cholesterol; mevinolin; pitavastatin; pravastatin; rosuvastatin; simvastatin; triacylglycerol; biological marker; hypocholesterolemic agent; low density lipoprotein cholesterol; adult; age; aged; Article; Asia; chronic kidney failure; computer assisted tomography; coronary angiography; disease assessment; Dyslipidemia International Study; ethnicity; female; follow up; human; hyperlipidemia; hypertension; ischemic heart disease; major clinical study; male; middle aged; mortality; non insulin dependent diabetes mellitus; observational study; priority journal; smoking; ST segment elevation myocardial infarction; stenosis; United States; acute coronary syndrome; blood; clinical practice; clinical trial; coronary artery disease; cross-sectional study; dyslipidemia; epidemiology; ethnology; multicenter study; practice guideline; protocol compliance; recurrent disease; risk factor; time factor; treatment outcome; Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Asia; Biomarkers; Cholesterol, LDL; Coronary Disease; Cross-Sectional Studies; Dyslipidemias; Female; Guideline Adherence; Humans; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Recurrence; Risk Factors; Time Factors; Treatment Outcome |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。